CY1120684T1 - Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης - Google Patents

Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης

Info

Publication number
CY1120684T1
CY1120684T1 CY181100948T CY181100948T CY1120684T1 CY 1120684 T1 CY1120684 T1 CY 1120684T1 CY 181100948 T CY181100948 T CY 181100948T CY 181100948 T CY181100948 T CY 181100948T CY 1120684 T1 CY1120684 T1 CY 1120684T1
Authority
CY
Cyprus
Prior art keywords
adrenergic
corticosteroids
inhalation
beta
dry dust
Prior art date
Application number
CY181100948T
Other languages
English (en)
Inventor
Elisa Monari
Anna Maria Cantarelli
Daniela Cocconi
Irene Pasquali
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120684(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CY1120684T1 publication Critical patent/CY1120684T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αφορά ένα σκεύασμα ξηρής σκόνης που περιλαμβάνει ένα κορτικοστεροειδές και μία βήτα2-αδρενεργική δραστική ουσία σε συνδυασμό, τη μέθοδο παρασκευής και θεραπευτικές χρήσεις αυτού.
CY181100948T 2012-01-25 2018-09-11 Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης CY1120684T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152392 2012-01-25
PCT/EP2013/051187 WO2013110632A1 (en) 2012-01-25 2013-01-23 Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
EP13704372.5A EP2806855B1 (en) 2012-01-25 2013-01-23 Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation

Publications (1)

Publication Number Publication Date
CY1120684T1 true CY1120684T1 (el) 2019-12-11

Family

ID=47715987

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100948T CY1120684T1 (el) 2012-01-25 2018-09-11 Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης

Country Status (38)

Country Link
US (3) US10028964B2 (el)
EP (7) EP2806855B1 (el)
JP (1) JP6104282B2 (el)
KR (3) KR101560288B1 (el)
CN (2) CN104080444B (el)
AR (1) AR089805A1 (el)
AU (1) AU2013211656B2 (el)
BR (1) BR112014017481A8 (el)
CA (1) CA2862548C (el)
CL (1) CL2014001966A1 (el)
CO (1) CO7010836A2 (el)
CY (1) CY1120684T1 (el)
DK (5) DK3412277T3 (el)
EA (2) EA031566B1 (el)
ES (5) ES2929807T3 (el)
FI (1) FI3412277T3 (el)
GE (1) GEP201706767B (el)
HK (1) HK1200021A1 (el)
HR (5) HRP20221432T1 (el)
HU (5) HUE060705T2 (el)
IL (1) IL233784A0 (el)
LT (5) LT3527199T (el)
MA (1) MA35859B1 (el)
MX (2) MX355729B (el)
MY (1) MY165888A (el)
NZ (1) NZ627837A (el)
PE (1) PE20141703A1 (el)
PH (1) PH12014501565A1 (el)
PL (5) PL3527199T3 (el)
PT (5) PT3527196T (el)
RS (5) RS63706B1 (el)
SG (1) SG11201404350PA (el)
SI (2) SI2806855T1 (el)
TN (1) TN2014000322A1 (el)
TW (1) TWI559940B (el)
UA (1) UA115543C2 (el)
WO (1) WO2013110632A1 (el)
ZA (1) ZA201405464B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3527199T (lt) * 2012-01-25 2022-12-12 Chiesi Farmaceutici S.P.A. Sausų miltelių pavidalo vaisto forma, apimanti kortikosteroidą ir beta-adrenerginį blokatorių, skirta vartoti inhaliacijos būdu
US9402825B2 (en) 2013-07-11 2016-08-02 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
UA118861C2 (uk) * 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій
US10517828B2 (en) 2014-10-08 2019-12-31 Zambon S.P.A. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
CN109789107B (zh) * 2016-09-29 2021-12-03 广东东阳光药业有限公司 药物组合物
EP3621590B1 (en) * 2017-05-11 2021-09-01 Chiesi Farmaceutici S.p.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
EP3687500A1 (en) 2017-09-29 2020-08-05 Crititech, Inc. Glucocorticoid particles and their use
ES2953293T3 (es) * 2018-08-07 2023-11-10 Norton Waterford Ltd Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
US20210370007A1 (en) 2018-10-30 2021-12-02 Chiesi Farmaceuticl S.p.A. Apparatus to administer drugs to mechanically ventilated patients
WO2021058454A1 (en) 2019-09-24 2021-04-01 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
AU2021324395A1 (en) 2020-08-14 2023-03-16 Norton (Waterford) Limited An inhalable formulation of fluticasone propionate and albuterol sulfate
WO2023117967A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
RO122660B1 (ro) * 1998-11-13 2009-11-30 Skypepharma Ag Pulbere inhalabilă uscată
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
ES2359576T5 (es) 2002-07-31 2020-03-03 Chiesi Farm Spa Inhalador de polvo
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB0914240D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Steroid solvates
ES2568913T3 (es) * 2009-10-02 2016-05-05 Chiesi Farmaceutici S.P.A. Formulaciones farmacéuticas en aerosol de formoterol y dipropionato de beclometasona
TR201811349T4 (tr) 2010-04-01 2018-09-21 Chiesi Farm Spa İnhalasyon i̇çi̇n kuru toz taşiyici parti̇külleri̇n hazirlanmasi i̇çi̇n proses.
HUE038555T2 (hu) * 2010-04-21 2018-10-29 Chiesi Farm Spa Eljárás csökkentett elektrosztatikus töltéssel rendelkezõ részecskék elõállítására
LT3527199T (lt) * 2012-01-25 2022-12-12 Chiesi Farmaceutici S.P.A. Sausų miltelių pavidalo vaisto forma, apimanti kortikosteroidą ir beta-adrenerginį blokatorių, skirta vartoti inhaliacijos būdu
US9402825B2 (en) * 2013-07-11 2016-08-02 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Also Published As

Publication number Publication date
RS63759B1 (sr) 2022-12-30
CL2014001966A1 (es) 2014-11-14
ES2929807T3 (es) 2022-12-01
HRP20221433T1 (hr) 2023-01-06
KR101560288B1 (ko) 2015-10-14
EP3527199A1 (en) 2019-08-21
EP3527198A1 (en) 2019-08-21
SG11201404350PA (en) 2014-08-28
PL3412277T3 (pl) 2023-06-19
BR112014017481A2 (pt) 2017-06-13
EP3527199B1 (en) 2022-09-07
CA2862548C (en) 2020-07-07
LT3527196T (lt) 2022-11-25
SI2806855T1 (sl) 2018-11-30
MX368199B (es) 2019-09-24
ES2938466T3 (es) 2023-04-11
TN2014000322A1 (en) 2015-12-21
PL3527199T3 (pl) 2022-12-12
TWI559940B (en) 2016-12-01
CN104080444A (zh) 2014-10-01
DK3412277T3 (da) 2023-02-20
HK1200021A1 (en) 2015-07-31
CN105726548B (zh) 2019-05-14
EP2806855A1 (en) 2014-12-03
TW201334810A (zh) 2013-09-01
HRP20221432T1 (hr) 2023-01-06
LT2806855T (lt) 2018-10-10
LT3527197T (lt) 2022-11-25
MX355729B (es) 2018-04-27
RS57637B1 (sr) 2018-11-30
HUE040525T2 (hu) 2019-03-28
EA201690187A1 (ru) 2016-05-31
HUE060421T2 (hu) 2023-02-28
KR20140114374A (ko) 2014-09-26
KR20170116234A (ko) 2017-10-18
EA201491281A1 (ru) 2014-12-30
CN105726548A (zh) 2016-07-06
HRP20221431T1 (hr) 2023-01-06
AR089805A1 (es) 2014-09-17
MX2014008631A (es) 2014-08-21
PT3527199T (pt) 2022-11-08
US8778402B2 (en) 2014-07-15
SI3412277T1 (sl) 2023-03-31
CO7010836A2 (es) 2014-07-31
US20180296573A1 (en) 2018-10-18
DK3527197T3 (da) 2022-10-24
RS63952B1 (sr) 2023-02-28
HUE060402T2 (hu) 2023-02-28
JP2015508416A (ja) 2015-03-19
LT3527199T (lt) 2022-12-12
HRP20230147T1 (hr) 2023-03-31
DK3527199T3 (da) 2022-10-24
EP3020394A1 (en) 2016-05-18
AU2013211656B2 (en) 2017-07-13
RS63761B1 (sr) 2022-12-30
MY165888A (en) 2018-05-18
PL3527197T3 (pl) 2022-11-21
US20150164915A1 (en) 2015-06-18
NZ627837A (en) 2016-04-29
JP6104282B2 (ja) 2017-03-29
PE20141703A1 (es) 2014-11-24
PL3527196T3 (pl) 2022-11-21
ES2683254T3 (es) 2018-09-25
FI3412277T3 (fi) 2023-03-23
EA026267B1 (ru) 2017-03-31
EP3412277B1 (en) 2022-12-14
ES2928688T3 (es) 2022-11-22
ZA201405464B (en) 2015-12-23
PT3527197T (pt) 2022-10-26
RS63706B1 (sr) 2022-11-30
CN104080444B (zh) 2017-06-20
AU2013211656A1 (en) 2014-07-24
PT3412277T (pt) 2023-02-14
EP3527197B1 (en) 2022-09-07
EA031566B1 (ru) 2019-01-31
LT3412277T (lt) 2023-04-25
PL2806855T3 (pl) 2018-12-31
GEP201706767B (en) 2017-11-10
EP3527196A1 (en) 2019-08-21
CA2862548A1 (en) 2013-08-01
WO2013110632A1 (en) 2013-08-01
HUE061566T2 (hu) 2023-07-28
PT3527196T (pt) 2022-10-18
EP3527196B1 (en) 2022-09-07
PT2806855T (pt) 2018-09-28
ES2929137T3 (es) 2022-11-25
PH12014501565B1 (en) 2014-10-08
KR20150089093A (ko) 2015-08-04
US10028964B2 (en) 2018-07-24
KR101895279B1 (ko) 2018-09-05
EP3412277A1 (en) 2018-12-12
BR112014017481A8 (pt) 2021-06-15
US10946029B2 (en) 2021-03-16
EP3527197A1 (en) 2019-08-21
HUE060705T2 (hu) 2023-04-28
HRP20181550T1 (hr) 2018-11-30
PH12014501565A1 (en) 2014-10-08
IL233784A0 (en) 2014-09-30
EP2806855B1 (en) 2018-07-11
KR101786586B1 (ko) 2017-10-18
DK3527196T3 (da) 2022-10-24
DK2806855T3 (en) 2018-09-03
UA115543C2 (uk) 2017-11-27
MA35859B1 (fr) 2014-12-01
US20130189324A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
CY1120684T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1120806T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
PL3083556T3 (pl) Lipidy i kompozycje lipidowe dla dostarczania środków czynnych
CY1124490T1 (el) Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
GT201400182A (es) Formulaciones farmacéuticas novedosas
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
UY34581A (es) Dispositivo de inhalación para fármacos en polvo
TR201909447T4 (tr) Aramkol tuzları.
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
TR201008226A2 (tr) Kapsül içeren bir inhalasyon cihazı.
EA201590405A1 (ru) Приготовление высушенных липосом для применения в системах выпуска в прессованном виде
CL2014003211A1 (es) Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
UY34579A (es) Dispositivo de inhalación para fármacos en polvo
CY1117884T1 (el) Διαδερμικη διαταξη που περιλαμβανει πορωδη μικροσωματιδια
CY1120545T1 (el) Συνθεση για τη θεραπεια της διαταραχης μειωμενης σεξουαλικης επιθυμιας
FR3012814B1 (fr) Composition polymere comprenant et liberant un compose actif odorant
CY1122538T1 (el) Συμπλεγματα χονδροϊτινης για διαδερμικη απορροφηση
UY34580A (es) Dispositivo de inhalación para fármacos en polvo
EA201690445A1 (ru) Лечение рака